This is India's first and only phase-3 efficacy study for a Covid-19 vaccine, and the largest phase-3 efficacy trial ever conducted for any vaccine in the country.
Leads a CSIR-NMITLI supported project that also involves National Centre for Cell Science and Indian Institute of Technology-Indore and PredOmix Technologies
They will work towards developing a cost-effective process with minimal dependency on China for key raw materials
"ICMR recommends that any testing with the Cepheid Xpert Xpress SARS CoV-2 is carried under Biosafety 2 level (BSL-2) conditions and with appropriate biosafety precautions."
This has come as a boon for public health care institutions as they focus on providing quality care to Covid cases
New Delhi: As SARS-CoV2, the new coronavirus that causes the COVID-19 disease, keeps wreaking havoc globally, a new study has come out with the...
"A total of 15,404 samples from 14,514 individuals have been tested for SARS-CoV2 as on 20th March 2020 6 PM. A total of 236 individuals have been confirmed positive among suspected cases and contacts of known positive cases," Indian Council for Medical Research (ICMR) said.
"The study material on coronavirus would be added to the new diploma course, which will be offered within the next two months."